Risk factors for the development of hypermagnesemia. BMC Nephrology. Multivariate analysis revealed that hyperphosphatemia and hs-CRP were the independent risk factors for CAC initiation after adjustments. Coronary artery calcification (CAC) contributes to high risk of cardiocerebrovascular diseases in dialysis patients. Bone and mineral metabolism becomes dysregulated with progression of chronic kidney disease (CKD), and increasing levels of parathyroid hormone serve as an adaptive response to maintain normal phosphorus and calcium levels. This information will be used to develop a patient specific phosphate binder application to facilitate patient self-management of serum phosphate. However, there are other conditions as well that might lead to the phosphate levels going out of balance. Hyperphosphataemia Is Associated with the Diabetes-related Cardiovascular Risk Factors Linear regression was performed to analyze associations between the average serum phosphate level and other factors. The most common cause of this illness is kidney disease. Hypophosphatemia is an abnormally low level of phosphate in the blood. These results suggested potential clinical strategies to prevent the initiation of CAC in PD patients. Two patients were dialyzed for renal failure due to hyperuricemia and one for renal failure due to hyperphosphatemia which developed shortly after starting chemotherapy. Renal insufficiency or renal failure is one of the common causes of hyperphosphatemia. Hyperphosphatemia in adults is defined as a serum phosphorus level greater than 5.0 mg/dl. kidney-speciï¬c risk factors, such as enhanced activity of the reninâangiotensin system, sympathetic overactivity, endothelial dysfunction (related to the accumulation of asymmetric dimethylarginine, chronic inï¬ammatory state, and oxidative stress), hyperphosphatemia, and CKD ⦠It causes the electrolytes to imbalance due to the cell dying and releasing intracellular contents into the blood, hence too much phosphate is released into the blood The prevalence of hyperphosphatemia in the general population and in persons with renal failure is similar throughout the world.Hyperphosphatemia is a well recognized risk factor for cardiovascular mortality in dialysis patients. Hyperphosphatemia has been associated with adverse outcomes in patients with end stage kidney disease (ESKD). The present study aimed to identify modifiable risk factors for... Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients | SpringerLink Observational studies have determined hyperphosphatemia to be a cardiovascular risk factor in chronic kidney disease. The risk factors for hyperphosphatemia. Lower body weight and female gender: Hyperphosphatemia risk factors after sodium phosphate preparations Parakkal Deepak and Eli D Ehrenpreis Parakkal Deepak, Department of Gastroenterology, NorthShore University Hospital, 2650 Ridge Ave Evanston, IL 60201-1718, United States The purpose of this study was to determine risk factors for hyperphosphatemia in ESKD patients treated with peritoneal dialysis (PD). Hyperphosphatemia and hs-CRP as Independent Risk Factors for CAC Initiation The two groups were weakly different in BMI ( p = 0.087), uric acid (UA) ( p = 0.087), Homa-IR ( p = 0.105), and residual CCR ( p = 0.056), while they were similar in hemoglobin, AKP, ferritin, cholesterol, LDL, iPTH, and adjusted calcium. Slowing kidney damage is the best way to reduce the risk of hyperphosphatemia [2]. Clin Transplant . Together they form a unique fingerprint. (2013) Wojcicki. Hyperphosphatemia is an independent risk factor contributing to the increased incidence of aortic and mitral stenosis and other cardiovascular diseases among patients who are dependent on dialysis. When there is too much phosphate in the blood, the condition is known as hyperphosphatemia [1]. Similar results have been reported with sodium phosphate enemas. A peripheral form known as calcific uremic arteriolopathy (calciphylaxis) can induce necrotic ulceration and gangrene in affected extremities. The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age. Fingerprint Dive into the research topics of 'Lower body weight and female gender: Hyperphosphatemia risk factors after sodium phosphate preparations'. Phosphate is an electrolyte that helps your body with energy production and nerve function. Hyperuricemia and/or hyperphosphatemia were presumed responsible for the development of azotemia in the post-chemotherapy period. For hyperphosphatemia, most studies had proved that hyperphosphatemia was an independent risk factor for mortality or morbidity [1,7,11,14,15,[20][21] [22] [23][24][25][26]. Hyperphosphatemia can weaken bones and cause damage to veins, tissues, and organs in the body. In addition to the traditional CVD risk factors, studies in dialysis patients have shown a correlation between CAC and a number of dialysis-related factors, such as dialysis vintage, hyperphosphatemia, high Ca × P product, and vitamin D therapy Table 3 The purpose of this study was to determine risk factors for hyperphosphatemia in ESKD patients treated with peritoneal dialysis (PD). Similar results have been reported with sodium phosphate enemas. In addition, compared with patients who had an eGFR of 60-89 mL/min/1.73 m2, those with an eGFR below 29 had a 2.3 times increased risk of hyperphosphatemia. Hyperphosphatemia and hs-CRP were the independent risk factors for CAC initiation in PD patients. [Medline] . Hyperphosphatemia is a risk factor for adverse outcome in patients on regular hemodialysis. Background. Increased age, abnormal bowel motility, and decreased kidney function are all risk factors for persistent and significant hyperphosphatemia. In advanced CKD, increased dietary phosphorus is associated with hyperphosphatemia. Increased age, abnormal bowel motility, and decreased kidney function are all risk factors for persistent and significant hyperphosphatemia. Hyperphosphatemia is commonly caused by the alteration of our renal system causing the decrease of renal excretion of phosphate. Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients BMC Nephrology , Jul 2015 Da Shang , Qionghong Xie , Xiaolin Ge , Huanqing Yan , Jing Tian , Dingwei Kuang , Chuan-Ming Hao , Tongying Zhu However, the association be-tween hyperphosphatemia and CAC progression re-mains controversial in ESRD patients on PD [10, 11, 13, 14, 25]. risk factors (London et al., 2003), the search for non-traditional risk factors has led to increasing evidence of a multitude of factors that contribute to ectopic calcification in CKD. However, the risk factors for CAC initiation in peritoneal dialysis (PD) patients are not known clearly. With regard to sudden death, two previous observational studies suggested an association between serum phosphate levels and the risk of sudden death in patients on hemodialysis[ 9 , 10 ]. This information will be used to develop a patient specific phosphate binder application to facilitate patient self-management of serum phosphate. 2011 Sep. 25(5):721-30. 1.2 High mortality rate and hyperphosphatemia Inorganic phosphate (phosphate) retention, or hyperphosphatemia⦠Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease Cardiovascular (CV) mortality in chronic kidney disease (CKD) associate with traditional risk factors (1) including dyslipidaemia, diabetes, smoking and left ventricular mass hypertrophy. Although the multi-collinearity among variables was evaluated, strong correlations (|correlation coefficient: r | > 0.7) were not observed. Methods. Indeed, patients with hyperphosphatemia on hemodialysis have an elevated risk of lethal forms of CVD, such as myocardial infarction and stroke [7,8]. Conclusions. Background: Hyperphosphatemia, serum phosphorus ⥠4.4 mg/dL, is associated with increased risk for chronic kidney disease and cardiovascular disease. Hyperphosphatemia - The Risk Factor for Adverse Outcome in Maintenance Hemodialysis Patients Hyperphosphatemia is a potent stimulator of vascular and valvular calcifications in hemodialysis patients. In end-stage renal disease, this response becomes maladaptive and high levels of phosphorus may occur. Marked elevation of phosphorus is due to these factors: Renal insufficiency â acute or chronic. Causes of hyperphosphatemia (S) Syndrome of Tumor Lysis is a metabolic problem that mainly occurs with treatment of cancer with chemotherapy. Mechanistic studies have elucidated that hyperphosphatemia is a direct stimulus to vascular calcification, which is one cause of morbid cardiovascular events contributing to the excess mortality of chronic kidney disease. Hyperphosphatemia has been associated with increases in vessel wall thickness and arterial stiffness [24]. Previous studies have shown a weak association between dietary phosphorus ⦠Binary logistic regression was performed to identify the independent risk factors for CAC progression in the PD patients, and multivariate linear regression was conducted to identify factors associated with hyperphosphatemia. PHILADELPHIAâHyperphosphatemia is an independent risk factor for coronary artery calcification (CAC) progression in patients undergoing peritoneal dialysis (PD), according to a â¦